Cargando…

The roles of glycolysis in osteosarcoma

Metabolic reprogramming is of great significance in the progression of various cancers and is critical for cancer progression, diagnosis, and treatment. Cellular metabolic pathways mainly include glycolysis, fat metabolism, glutamine decomposition, and oxidative phosphorylation. In cancer cells, rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zuxi, Ou, Yanghuan, Hao, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428632/
https://www.ncbi.nlm.nih.gov/pubmed/36059961
http://dx.doi.org/10.3389/fphar.2022.950886
_version_ 1784779161566445568
author Feng, Zuxi
Ou, Yanghuan
Hao, Liang
author_facet Feng, Zuxi
Ou, Yanghuan
Hao, Liang
author_sort Feng, Zuxi
collection PubMed
description Metabolic reprogramming is of great significance in the progression of various cancers and is critical for cancer progression, diagnosis, and treatment. Cellular metabolic pathways mainly include glycolysis, fat metabolism, glutamine decomposition, and oxidative phosphorylation. In cancer cells, reprogramming metabolic pathways is used to meet the massive energy requirement for tumorigenesis and development. Metabolisms are also altered in malignant osteosarcoma (OS) cells. Among reprogrammed metabolisms, alterations in aerobic glycolysis are key to the massive biosynthesis and energy demands of OS cells to sustain their growth and metastasis. Numerous studies have demonstrated that compared to normal cells, glycolysis in OS cells under aerobic conditions is substantially enhanced to promote malignant behaviors such as proliferation, invasion, metastasis, and drug resistance of OS. Glycolysis in OS is closely related to various oncogenes and tumor suppressor genes, and numerous signaling pathways have been reported to be involved in the regulation of glycolysis. In recent years, a vast number of inhibitors and natural products have been discovered to inhibit OS progression by targeting glycolysis-related proteins. These potential inhibitors and natural products may be ideal candidates for the treatment of osteosarcoma following hundreds of preclinical and clinical trials. In this article, we explore key pathways, glycolysis enzymes, non-coding RNAs, inhibitors, and natural products regulating aerobic glycolysis in OS cells to gain a deeper understanding of the relationship between glycolysis and the progression of OS and discover novel therapeutic approaches targeting glycolytic metabolism in OS.
format Online
Article
Text
id pubmed-9428632
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94286322022-09-01 The roles of glycolysis in osteosarcoma Feng, Zuxi Ou, Yanghuan Hao, Liang Front Pharmacol Pharmacology Metabolic reprogramming is of great significance in the progression of various cancers and is critical for cancer progression, diagnosis, and treatment. Cellular metabolic pathways mainly include glycolysis, fat metabolism, glutamine decomposition, and oxidative phosphorylation. In cancer cells, reprogramming metabolic pathways is used to meet the massive energy requirement for tumorigenesis and development. Metabolisms are also altered in malignant osteosarcoma (OS) cells. Among reprogrammed metabolisms, alterations in aerobic glycolysis are key to the massive biosynthesis and energy demands of OS cells to sustain their growth and metastasis. Numerous studies have demonstrated that compared to normal cells, glycolysis in OS cells under aerobic conditions is substantially enhanced to promote malignant behaviors such as proliferation, invasion, metastasis, and drug resistance of OS. Glycolysis in OS is closely related to various oncogenes and tumor suppressor genes, and numerous signaling pathways have been reported to be involved in the regulation of glycolysis. In recent years, a vast number of inhibitors and natural products have been discovered to inhibit OS progression by targeting glycolysis-related proteins. These potential inhibitors and natural products may be ideal candidates for the treatment of osteosarcoma following hundreds of preclinical and clinical trials. In this article, we explore key pathways, glycolysis enzymes, non-coding RNAs, inhibitors, and natural products regulating aerobic glycolysis in OS cells to gain a deeper understanding of the relationship between glycolysis and the progression of OS and discover novel therapeutic approaches targeting glycolytic metabolism in OS. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428632/ /pubmed/36059961 http://dx.doi.org/10.3389/fphar.2022.950886 Text en Copyright © 2022 Feng, Ou and Hao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Feng, Zuxi
Ou, Yanghuan
Hao, Liang
The roles of glycolysis in osteosarcoma
title The roles of glycolysis in osteosarcoma
title_full The roles of glycolysis in osteosarcoma
title_fullStr The roles of glycolysis in osteosarcoma
title_full_unstemmed The roles of glycolysis in osteosarcoma
title_short The roles of glycolysis in osteosarcoma
title_sort roles of glycolysis in osteosarcoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428632/
https://www.ncbi.nlm.nih.gov/pubmed/36059961
http://dx.doi.org/10.3389/fphar.2022.950886
work_keys_str_mv AT fengzuxi therolesofglycolysisinosteosarcoma
AT ouyanghuan therolesofglycolysisinosteosarcoma
AT haoliang therolesofglycolysisinosteosarcoma
AT fengzuxi rolesofglycolysisinosteosarcoma
AT ouyanghuan rolesofglycolysisinosteosarcoma
AT haoliang rolesofglycolysisinosteosarcoma